Pharmaceutical shares staged a robust rebound on Monday, recovering from final week’s sharp decline after readability emerged on the scope of recent US tariffs on imported medication.
Shares of Wockhardt rallied over 10%, main the restoration within the sector. Bajaj Healthcare, Supriya Lifescience, Alembic Prescribed drugs, Aster DM Healthcare, Solar Pharmaceutical Industries, Lupin, Cipla, Aarti Medicine, Zydus Lifesciences, Biocon, and others gained between 1–3%.
The Nifty Pharma index superior over 1%, pushed by key constituents corresponding to Solar Pharma, Lupin, Cipla, Zydus Lifesciences, JB Chemical substances & Prescribed drugs, and Biocon.
The restoration in pharma shares right this moment comes after a steep correction on Friday, when US President Donald Trump introduced a 100% tariff on branded and patented pharmaceutical merchandise efficient October 1, except corporations manufacture within the US.
Nonetheless, sentiment improved considerably on Monday after it was clarified that the proposed tariffs would apply solely to branded and patented medication, not generic medicines, which type the majority of Indian exports to the US.
Restricted Impression on Indian Pharma Firms
Analysts count on minimal affect on Indian pharma corporations, given their dominant give attention to the generics market.
“India exports about $8.7 billion value of prescription drugs to the US, comprising roughly a 3rd of its complete pharma exports. For a lot of Indian companies, the US market accounts for 30–50% of their income. Whereas generic medication, which make up 90% of US drug volumes are largely unaffected, the latest 100% tariff on imported branded medication is growing prices, risking value hikes and provide disruptions,” stated Om Ghawalkar, Market Analyst, Share.Market (PhonePe Wealth).
He added that Indian drugmakers are actively diversifying into rising markets like Africa and Latin America and investing extra closely in biosimilars and modern drug growth to scale back dependence on the US.
“Within the brief time period, the sector faces inventory dips and margin pressures. Nonetheless, the long-term outlook is a strategic shift towards bolstering home US provide chains and innovation. This pivot could reshape international pharma manufacturing, positioning corporations investing in US manufacturing for larger market resilience and desire,” stated Ghawalkar.
‘Enterprise as Regular’ for Generics
Tushar Manudhane, Senior Vice President and Healthcare Analysis Analyst at Motilal Oswal Monetary Providers, believes the affect on Indian exporters will likely be negligible.
“There can be no affect on generics exports by Indian pharma corporations, as the majority of shipments to the US include generic medicines. Even for CDMOs, they usually provide components of the product moderately than the completed formulation for innovator corporations. CDMOs additionally cater to the worldwide wants of innovator pharma gamers, not simply the US market,” he stated.
He additional identified that uncooked supplies account for less than 4–5% of gross sales for innovator corporations. Given the complexities round switching suppliers — functionality, capability, and compliance — he expects prices to be both absorbed by innovators or handed on to customers.
“The innovator has a restricted interval of patent exclusivity and want to make the most of the time to maximise the gross sales. We nonetheless await the chief order for detailed understanding of tariffs on medication,” Manudhane stated.
Warning Amid Coverage Uncertainty
Regardless of the rebound, some analysts stay guarded.
Ajit Mishra, Senior Vice President, Analysis at Religare Broking, stated, “The uncertainty round future coverage shifts retains nerves on edge. For Indian pharma giants, it is a wake-up name to strengthen provide chains and discover US-based manufacturing, even because the sector’s core power in inexpensive generics continues to help international healthcare.”
Disclaimer: The views and proposals made above are these of particular person analysts or broking corporations, and never of Mint. We advise buyers to examine with licensed specialists earlier than making any funding choices.
